CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome

Jose Alberto Choreño-Parra, Luis Armando Jiménez-Álvarez, Gustavo Ramírez-Martínez, Montserrat Sandoval-Vega, Citlaltepetl Salinas-Lara, Carlos Sánchez-Garibay, Cesar Luna-Rivero, Erika Mariana Hernández-Montiel, Luis Alejandro Fernández-López, María Fernanda Cabrera-Cornejo, Eduardo Misael Choreño-Parra, Alfredo Cruz-Lagunas, Andrea Domínguez, Eduardo Márquez-García, Carlos Cabello-Gutiérrez, Francina Valezka Bolaños-Morales, Lourdes Mena-Hernández, Diego Delgado-Zaldivar, Daniel Rebolledo-García, Parménides Guadarrama-OrtizNora E. Regino-Zamarripa, Criselda Mendoza-Milla, Ethel A. García-Latorre, Tatiana Sofia Rodiguez-Reyna, Diana Cervántes-Rosete, Carmen M. Hernández-Cárdenas, Shabaana A. Khader, Albert Zlotnik, Joaquín Zúñiga

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The C-X-C motif chemokine ligand 17 (CXCL17) is chemotactic for myeloid cells, exhibits bactericidal activity, and exerts anti-viral functions. This chemokine is constitutively expressed in the respiratory tract, suggesting a role in lung defenses. However, little is known about the participation of CXCL17 against relevant respiratory pathogens in humans. Here, we evaluated the serum levels and lung tissue expression pattern of CXCL17 in a cohort of patients with severe pandemic influenza A(H1N1) from Mexico City. Peripheral blood samples obtained on admission and seven days after hospitalization were processed for determinations of serum CXCL17 levels by enzyme-linked immunosorbent assay (ELISA). The expression of CXCL17 was assessed by immunohistochemistry (IHQ) in lung autopsy specimens from patients that succumbed to the disease. Serum CXCL17 levels were also analyzed in two additional comparative cohorts of coronavirus disease 2019 (COVID-19) and pulmonary tuberculosis (TB) patients. Additionally, the expression of CXCL17 was tested in lung autopsy specimens from COVID-19 patients. A total of 122 patients were enrolled in the study, from which 68 had pandemic influenza A(H1N1), 24 had COVID-19, and 30 with PTB. CXCL17 was detected in post-mortem lung specimens from patients that died of pandemic influenza A(H1N1) and COVID-19. Interestingly, serum levels of CXCL17 were increased only in patients with pandemic influenza A(H1N1), but not COVID-19 and PTB. CXCL17 not only differentiated pandemic influenza A(H1N1) from other respiratory infections but showed prognostic value for influenza-associated mortality and renal failure in machine-learning algorithms and regression analyses. Using cell culture assays, we also identified that human alveolar A549 cells and peripheral blood monocyte-derived macrophages increase their CXCL17 production capacity after influenza A(H1N1) pdm09 virus infection. Our results for the first time demonstrate an induction of CXCL17 specifically during pandemic influenza A(H1N1), but not COVID-19 and PTB in humans. These findings could be of great utility to differentiate influenza and COVID-19 and to predict poor prognosis specially at settings of high incidence of pandemic A(H1N1). Future studies on the role of CXCL17 not only in severe pandemic influenza, but also in seasonal influenza, COVID-19, and PTB are required to validate our results.

Original languageEnglish
Article number633297
JournalFrontiers in immunology
StatePublished - Feb 26 2021


  • COVID-19
  • CXCL17
  • SARS-CoV-2
  • chemokines
  • influenza A(H1N1)
  • tuberculosis


Dive into the research topics of 'CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome'. Together they form a unique fingerprint.

Cite this